$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti

$rmti Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000162828023017994 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$18.08M	$19.67M	$19.31M
YoY Change	-3.22%	21.98%	25.97%
Cost Of Revenue	$17.05M	$17.07M	$16.97M
YoY Change	0.65%	0.94%	-3.36%
Gross Profit	$1.033M	$2.599M	$2.340M
YoY Change	-40.8%	-430.66%	-204.89%
Gross Profit Margin	5.71%	13.21%	12.12%
Selling, General & Admin	$3.825M	$3.748M	$4.150M
YoY Change	-27.84%	-12.29%	-12.41%
% of Gross Profit	370.28%	144.21%	177.35%
Research & Development	$167.0K	$278.0K	$156.0K
YoY Change	-81.97%	-82.26%	-88.78%
% of Gross Profit	16.17%	10.7%	6.67%
Depreciation & Amortization	$200.0K	$160.0K	$156.0K
YoY Change	100.0%	15.94%	17.29%
% of Gross Profit	19.36%	6.16%	6.67%
Operating Expenses	$3.992M	$4.026M	$4.306M
YoY Change	-35.89%	-31.06%	-29.73%
Operating Profit	-$2.959M	-$1.427M	-$1.966M
YoY Change	-33.98%	-78.46%	-76.48%
Interest Expense	$395.0K	$387.0K	-$394.0K
YoY Change	-18.56%	-28.33%	-32.3%
% of Operating Profit
Other Income/Expense, Net	-$346.0K	-$323.0K
YoY Change	-28.66%	-39.74%
Pretax Income	-$3.305M	-$1.750M	-$2.360M
YoY Change	-33.46%	-75.57%	-73.6%
Income Tax
% Of Pretax Income
Net Earnings	-$3.305M	-$1.750M	-$2.360M
YoY Change	-33.46%	-75.57%	-73.6%
Net Earnings / Revenue	-18.28%	-8.9%	-12.22%
Basic Earnings Per Share	-$0.18	-$0.10
Diluted Earnings Per Share	-$0.18	-$0.10	-$0.20
COMMON SHARES
Basic Shares Outstanding	13.74M shares	12.55M shares	11.63M shares
Diluted Shares Outstanding	18.50M shares	18.36M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.87M	$16.83M	$21.49M
YoY Change	-51.74%	70.04%	-4.22%
Cash & Equivalents	$8.959M	$10.89M	$10.10M
Short-Term Investments	$5.906M	$5.940M	$11.39M
Other Short-Term Assets	$1.475M	$1.240M	$1.745M
YoY Change	-53.96%	-44.42%	-39.01%
Inventory	$5.814M	$5.595M	$5.814M
Prepaid Expenses
Receivables	$5.411M	$6.021M	$6.259M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$27.57M	$29.69M	$35.31M
YoY Change	-41.66%	19.73%	0.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.093M	$2.179M	$2.194M
YoY Change	-8.56%	-8.33%	-11.75%
Goodwill	$921.0K	$921.0K	$900.0K
YoY Change	0.0%	0.0%	-2.28%
Intangibles			$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$527.0K	$522.0K	$523.0K
YoY Change	3.54%	-15.53%	-15.51%
Total Long-Term Assets	$10.47M	$10.78M	$11.33M
YoY Change	-11.79%	-14.69%	-14.76%
TOTAL ASSETS
Total Short-Term Assets	$27.57M	$29.69M	$35.31M
Total Long-Term Assets	$10.47M	$10.78M	$11.33M
Total Assets	$38.04M	$40.47M	$46.64M
YoY Change	-35.66%	8.11%	-3.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.927M	$5.202M	$4.053M
YoY Change	101.46%	23.15%	8.4%
Accrued Expenses	$3.763M	$4.359M	$7.702M
YoY Change	-19.25%	-0.32%	51.32%
Deferred Revenue	$259.0K	$259.0K	$1.731M
YoY Change	-88.06%	-88.03%	-20.27%
Short-Term Debt	$733.0K	$0.00	$503.0K
YoY Change	-51.42%		15.1%
Long-Term Debt Due	$4.631M	$3.131M	$1.631M
YoY Change	-9.74%	-52.78%	-77.9%
Total Short-Term Liabilities	$17.45M	$15.07M	$17.69M
YoY Change	-5.84%	-23.09%	-15.62%
LONG-TERM LIABILITIES
Long-Term Debt	$4.740M	$6.147M	$7.555M
YoY Change	-54.29%	-47.81%	-42.7%
Other Long-Term Liabilities	$14.00K	$14.00K	$14.00K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Liabilities	$4.754M	$6.161M	$7.569M
YoY Change	-54.22%	-47.75%	-42.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.45M	$15.07M	$17.69M
Total Long-Term Liabilities	$4.754M	$6.161M	$7.569M
Total Liabilities	$28.51M	$27.93M	$32.53M
YoY Change	-26.85%	-33.88%	-29.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$393.8M	-$390.5M	-$388.8M
YoY Change	3.04%	3.53%	5.06%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.528M	$12.54M	$14.10M
YoY Change
Total Liabilities & Shareholders Equity	$38.04M	$40.47M	$46.64M
YoY Change	-35.66%	8.11%	-3.99%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$3.305M	-$1.750M	-$2.360M
YoY Change	-33.46%	-75.57%	-73.6%
Depreciation, Depletion And Amortization	$200.0K	$160.0K	$156.0K
YoY Change	100.0%	15.94%	17.29%
Cash From Operating Activities	-$1.736M	-$3.900M	-$594.0K
YoY Change	-70.61%	-60.2%	-93.42%
INVESTING ACTIVITIES
Capital Expenditures	$75.00K	-$52.00K	$81.00K
YoY Change	-247.06%	79.31%	-171.05%
Acquisitions
YoY Change
Other Investing Activities	$13.00K	$10.86M	$3.305M
YoY Change		18.58%	405.35%
Cash From Investing Activities	-$62.00K	$5.302M	$3.214M
YoY Change	21.57%	-41.95%	495.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-131.0K	-$631.0K	-5.498M
YoY Change	-100.49%	-76.52%	238.55%
NET CHANGE
Cash From Operating Activities	-1.736M	-$3.900M	-594.0K
Cash From Investing Activities	-62.00K	$5.302M	3.214M
Cash From Financing Activities	-131.0K	-$631.0K	-5.498M
Net Change In Cash	-1.929M	$792.0K	-2.878M
YoY Change	-109.24%	-123.53%	-71.53%
FREE CASH FLOW
Cash From Operating Activities	-$1.736M	-$3.900M	-$594.0K
Capital Expenditures	$75.00K	-$52.00K	$81.00K
Free Cash Flow	-$1.811M	-$3.848M	-$675.0K
YoY Change	-69.07%	-60.62%	-92.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.09
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001041024
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.09
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-23661
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ROCKWELL MEDICAL, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3317208
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	30142 S. Wixom Road
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Wixom
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48393
CY2023Q1	dei	City Area Code CityAreaCode	248
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	960-9009
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001
CY2023Q1	dei	Trading Symbol TradingSymbol	RMTI
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13743673	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10894000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10102000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	5940000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11390000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6021000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6259000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	5595000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5814000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1240000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1745000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	29690000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	35310000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2179000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2194000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	1276000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1276000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3558000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3943000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2326000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	2468000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	921000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	921000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	522000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	523000	usd
CY2023Q1	us-gaap	Assets Assets	40472000	usd
CY2022Q4	us-gaap	Assets Assets	46635000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5202000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4053000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4359000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7702000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1473000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1483000	usd
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	532000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	522000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	259000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1731000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	3131000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1631000	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	0	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	503000	usd
CY2023Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	114000	usd
CY2022Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	66000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15070000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17691000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2214000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2581000	usd
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1950000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2088000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6147000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	7555000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2535000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2600000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	27930000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	32529000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2023Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2022Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12552673	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12552673	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12163673	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12163673	shares
CY2023Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2022Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	402894000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	402701000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-390509000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388759000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	156000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	163000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12542000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14106000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40472000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46635000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19668000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	16124000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	17069000	usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	16910000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	2599000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	-786000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	278000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1567000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	498000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	455000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3250000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3818000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1427000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6626000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	4000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	387000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	540000	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	64000	usd
CY2022Q1	us-gaap	Investment Income Net InvestmentIncomeNet	0	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-323000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-536000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1750000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18359940	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18359940	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8544225	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8544225	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1750000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1757000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7163000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14106000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1750000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	193000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12542000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2535000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-179000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-4807000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1750000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	160000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	193000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	-179000	usd
CY2023Q1	rmti	Operating And Finance Lease Right Of Use Asset Amortization Expense OperatingAndFinanceLeaseRightOfUseAssetAmortizationExpense	485000	usd
CY2022Q1	rmti	Operating And Finance Lease Right Of Use Asset Amortization Expense OperatingAndFinanceLeaseRightOfUseAssetAmortizationExpense	520000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	92000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	92000	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2022Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	4000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-238000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1208000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-219000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1455000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-505000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-630000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1149000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	485000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-336000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-490000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-3295000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-640000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1537000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-538000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	3057000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	3216000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3876000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9811000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2053000	usd
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2810000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	7500000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11972000	usd
CY2023Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	145000	usd
CY2022Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	29000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5302000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9133000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	2250000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	503000	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	437000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	128000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-631000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2687000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	792000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3366000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10102000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13280000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10894000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9914000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	295000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	461000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-3000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	usd
CY2023Q1	rmti	Number Of Facilities NumberOfFacilities	3	facility
CY2023Q1	rmti	Area Of Operating Space AreaOfOperatingSpace	175000	sqft
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	16800000	usd
CY2023Q1	rmti	Working Capital Net WorkingCapitalNet	14600000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3900000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div>
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1750000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1750000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1750000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7162000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7162000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18359940	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18359940	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8544225	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8544225	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.84
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.84
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12879997	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2942516	shares
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	rmti	Number Of Distribution And License Agreements NumberOfDistributionAndLicenseAgreements	5	agreement
CY2023Q1	rmti	Average Payment Term Of Customers AveragePaymentTermOfCustomers	P30D
CY2023Q1	rmti	Average Payment Term Of Distributors AveragePaymentTermOfDistributors	P60D
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	19668000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	16124000	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	6021000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	6259000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2794000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4331000	usd
CY2023Q1	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	usd
CY2022Q1	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2800000	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	5868000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	72000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	5940000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	11315000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	75000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11390000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2806000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3351000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	504000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	351000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2285000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2112000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	5595000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5814000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	1276000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	1276000	usd
CY2023Q1	rmti	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	6871000	usd
CY2022Q4	rmti	Inventory Current And Noncurrent InventoryCurrentAndNoncurrent	7090000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9975000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9830000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7796000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7636000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2179000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2194000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4359000	usd
CY2023Q1	rmti	Research And Development Related Liabilities Current ResearchAndDevelopmentRelatedLiabilitiesCurrent	0	usd
CY2022Q4	rmti	Research And Development Related Liabilities Current ResearchAndDevelopmentRelatedLiabilitiesCurrent	43000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1804000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2568000	usd
CY2023Q1	rmti	Accrued Unvouchered Receipts Current AccruedUnvoucheredReceiptsCurrent	358000	usd
CY2022Q4	rmti	Accrued Unvouchered Receipts Current AccruedUnvoucheredReceiptsCurrent	585000	usd
CY2023Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	303000	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	306000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1894000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4200000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7702000	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	15000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	15000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12552673	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12552673	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12163673	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12163673	shares
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11486741	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12552673	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8544225	shares
CY2023Q1	rmti	Common Stock And Pre Funded Warrants Shares Outstanding CommonStockAndPreFundedWarrantsSharesOutstanding	18463673	shares
CY2022Q1	rmti	Common Stock And Pre Funded Warrants Shares Outstanding CommonStockAndPreFundedWarrantsSharesOutstanding	8544225	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1194202	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	511117	shares
CY2023Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	1363636	shares
CY2022Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	0	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	31343670	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	193000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	-179000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	6227	shares
CY2018Q4	rmti	Number Of Additional Agreements NumberOfAdditionalAgreements	3	agreement
CY2023Q1	rmti	Operating Lease And Finance Lease Liability OperatingLeaseAndFinanceLeaseLiability	6200000	usd
CY2023Q1	rmti	Operating Lease And Finance Lease Right Of Use Assets Net OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet	5900000	usd
CY2022Q4	rmti	Operating Lease And Finance Lease Liability OperatingLeaseAndFinanceLeaseLiability	6700000	usd
CY2022Q4	rmti	Operating Lease And Finance Lease Right Of Use Assets Net OperatingLeaseAndFinanceLeaseRightOfUseAssetsNet	6400000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	344000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	449000	usd
CY2023Q1	rmti	Operating Lease Interest Expense OperatingLeaseInterestExpense	60000	usd
CY2022Q1	rmti	Operating Lease Interest Expense OperatingLeaseInterestExpense	0	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	115000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	95000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	519000	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	544000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	141000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	141000	usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	39000	usd
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	47000	usd
CY2023Q1	rmti	Finance Lease Expense FinanceLeaseExpense	180000	usd
CY2022Q1	rmti	Finance Lease Expense FinanceLeaseExpense	188000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	703000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	736000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	424000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	464000	usd
CY2023Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	39000	usd
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	47000	usd
CY2023Q1	rmti	Cash Flows From Finance Lease Principal Payments CashFlowsFromFinanceLeasePrincipalPayments	128000	usd
CY2022Q1	rmti	Cash Flows From Finance Lease Principal Payments CashFlowsFromFinanceLeasePrincipalPayments	118000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P5Y2M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.064
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.064
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1249000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	502000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1405000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	672000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	937000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	676000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	310000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	666000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	121000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	311000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4022000	usd
CY2023Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2827000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	335000	usd
CY2023Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	345000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3687000	usd
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	2482000	usd

Files In Submission

Name	View Source	Status
0001628280-23-017994-index-headers.html	Edgar Link	pending
0001628280-23-017994-index.html	Edgar Link	pending
0001628280-23-017994.txt	Edgar Link	pending
0001628280-23-017994-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rmti-20230331.htm	Edgar Link	pending
rmti-20230331.xsd	Edgar Link	pending
rmti-20230331x10qex311.htm	Edgar Link	pending
rmti-20230331x10qex321.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rmti-20230331_def.xml	Edgar Link	unprocessable
rmti-20230331_lab.xml	Edgar Link	unprocessable
rmti-20230331_htm.xml	Edgar Link	completed
rmti-20230331_cal.xml	Edgar Link	unprocessable
rmti-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti

2023 Q2 Form 10-Q Financial Statement

#000162828023017994 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTI ROCKWELL MEDICAL, INC. Stock $rmti

2023 Q2 Form 10-Q Financial Statement

#000162828023017994 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti